MY ACCOUNT | NEWSLETTER |

Feline oral squamous cell carcinoma: recent advances and future perspectives


Feline oral squamous cell carcinoma (FOSCC) is the most common oral malignancy in cats, characterized by aggressive local invasion, high metastatic potential, and poor clinical outcomes. Its etiology is multifactorial, involving genetic mutations (notably TP53), viral infections (such as papillomavirus), environmental exposures to xenobiotics and chronic oral inflammation, though definitive causal relationships remain unclear due to limited studies.

FOSCC primarily affects older, non-pedigree cats, with no clear sex or breed predisposition, and most frequently arises in the gingiva, sublingual region, and tongue. FOSCC presents with non-specific signs like weight loss, oral ulceration, and difficult eating, often leading to late diagnosis. FOSCC displays highly infiltrative growth with marked cellular pleomorphism and frequent bone invasion. Recent advances have identified various biomarkers, such as Ki-67, Cyclin D1, Bmi-1, and EMT-related proteins, that enhance diagnostic accuracy and prognostic assessment, while emerging research into tumor mutational burden and metabolic pathways offers promising therapeutic targets.

Prognosis remains poor, with median survival times typically under 2 months and limited response to conventional treatments; however, surgical intervention and novel targeted therapies show potential for improved outcomes. This review synthesizes recent progress in understanding FOSCC etiology, pathology, and therapeutic strategies, and highlights ongoing challenges and future directions in the management of this devastating feline cancer.


Authors: Paul Tutu, Florentina Daraban Bocaneti, Gennaro Altamura, Mihaela Anca Dascalu, Loredana Horodincu, Octavian Dumitru Soreanu, Oana Irina Tanase, Giuseppe Borzacchiello, Mihai Mares

Source: https://www.frontiersin.org/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Hegg Named Associate Dean for Graduate Studies

Like0
Dislike0

Bond Vet Launches Membership Program Aimed at Expanding Access and Improving Pet Health Outcomes

Like0
Dislike0

Update in feline therapeutics: clinical use of 10 emerging therapies

Like0
Dislike0

Canine osteoarthritis and treatments: a review

Like0
Dislike0

Supportive Therapy of the Toxic Cow

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top